The preclinical data presented herein supports mechanisms of action for the clinical antitumor activity observed with zanidatamab as monotherapy and the potential differentiation of zanidatamab from trastuzumab and tras + pert, which are part of the current standards of care for HER2-positive gastric and breast cancers, respectively. This evidence concerns the gene ERBB2 and breast cancer.